Company / Cash & Equivalents
Tarsus Pharmaceuticals, Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$183.6M
FY2025
5-year range
$71.7M / $224.9M
FY2021-FY2025
Trend
+93.7%
vs FY2024
Sector context
#94 of 207
Health Care
What the data says
At $184M, Tarsus Pharmaceuticals, Inc.'s cash & equivalents ranks #94 of 207 in the Health Care sector. Cash & Equivalents has fluctuated over the past 7 years, ranging from $58M in FY2019 to $225M in FY2023.
Based on SEC 10-K filings.
$184M in FY2025 with a 5-year CAGR of +1.8%.
Declined from $225M to $184M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +36.8%
- 5-Year CAGR
- +1.8%
- 10-Year CAGR
- -
Sector benchmark
#94 of 207 in Health CareTop 45% of 207This company $183.6M Sector average $669.5M
▼
-72.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +1.8%, indicating consistent growth.
- In FY2025, cash & equivalents increased 93.7% year-over-year.
- Ranks #94 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $183.6M | +93.7% |
| FY2024 | $94.8M | -57.8% |
| FY2023 | $224.9M | +213.9% |
| FY2022 | $71.7M | -58.2% |
| FY2021 | $171.3M | +1.9% |
| FY2020 | $168.1M | +190.1% |
| FY2019 | $58.0M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026